child in hospital bed
child in hospital bed Scientists, including UCL experts, have found new insights into why some children have a longer remission than others after receiving CAR T-cell therapy for leukaemia. The collaborative research project, published in Nature Medicine , used clinical expertise and state-of-the-art computational analysis to identify a genetic signature of CAR T-cells that will be the most effective in the long term. CAR T-cells are genetically engineered T-cells (a type of immune cell), that are designed to target leukaemia. In recent years, they have become an established treatment option for children with a relapsed or incurable rare form of blood cancer called B-cell acute lymphoblastic leukaemia (B ALL). One of the key factors that determine whether the treatment will lead to a durable remission in leukaemia - allowing children to live cancer free - is how long the CAR T-cells last in the body. Until now, little has been known about what makes these cells last and, therefore, whether the treatment is likely to work long-term, without the need for further therapy. A collaborative research team from across UCL Great Ormond Street Institute of Child Health (UCL GOS ICH), Great Ormond Street Hospital (GOSH) and the Wellcome Sanger Institute, worked with families for years after their CAR T-cell treatment (called AUTO1), as part of the CARPALL study, to begin to build a picture of why some CAR T-cells stay in the body long-term.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
